Recombinant Human EDA protein

中文名： 外异蛋白A(EDA)重组蛋白
别名： EDA；ED1；EDA2；Ectodysplasin-A

货号: PA1000-9161

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	EDA
Uniprot No	Q92838
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	245-391aa
氨基酸序列	ENQPAVVHLQGQGSAIQVKNDLSGGVLNDWSRITMNPKVFKLHPRSGELE VLVDGTYFIYSQVEVYYINFTDFASYEVVVDEKPFLQCTRSIETGKTNYN TCYTAGVCLLKARQKIAVKMVHADISINMSKHTTFFGAIRLGEAPAS
预测分子量	20 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于EDA重组蛋白的3篇参考文献及其摘要概括：

1. **文献名称**: "Production of recombinant EDA protein and its functional characterization in vitro"

**作者**: Smith A, et al.

**摘要**: 该研究描述了一种在大肠杆菌中高效表达重组EDA蛋白的方法，并通过体外实验验证其与EDAR受体的结合能力，证实其可激活下游NF-κB信号通路。

2. **文献名称**: "Therapeutic efficacy of recombinant EDA in a murine model of X-linked hypohidrotic ectodermal dysplasia"

**作者**: Chen L, Wang Y.

**摘要**: 研究通过动物模型证明，重组EDA蛋白能恢复EDA基因缺陷小鼠的汗腺、牙齿和毛发发育，为治疗X连锁少汗性外胚层发育不良提供实验依据。

3. **文献名称**: "Structural insights into recombinant EDA-A1 isoform and its interaction with EDAR"

**作者**: Johnson R, et al.

**摘要**: 利用X射线晶体学解析重组EDA-A1异构体的三维结构，揭示其与EDAR受体结合的关键结构域，为靶向药物设计提供基础。

4. **文献名称**: "Optimizing recombinant EDA production in mammalian cell culture: A comparative study"

**作者**: Kim S, et al.

**摘要**: 比较HEK293和CHO细胞系统中重组EDA蛋白的表达效率，优化培养条件以提高产量，并证明哺乳细胞表达的蛋白具有更佳的生物活性。

(注：以上文献为示例，实际引用时建议通过PubMed或Google Scholar检索真实文献。)

背景信息

**Background of EDA Recombinant Protein**

The EDA (Ectodysplasin A) recombinant protein is a biologically engineered molecule derived from the EDA gene, which plays a critical role in embryonic development, particularly in the formation of ectodermal tissues such as skin, hair, teeth, and sweat glands. EDA belongs to the tumor necrosis factor (TNF) ligand family and exists in two major splice variants: EDA-A1 and EDA-A2. EDA-A1. the most studied isoform, interacts with the EDAR (EDA receptor) to activate the NF-κB signaling pathway, essential for ectodermal organogenesis.

Mutations in the EDA gene are linked to X-linked hypohidrotic ectodermal dysplasia (XLHED), a genetic disorder characterized by impaired development of hair, teeth, and sweat glands. Recombinant EDA protein has emerged as a therapeutic candidate to address this condition. By mimicking the natural EDA-A1 protein, it can potentially restore signaling pathways disrupted by genetic mutations, promoting proper ectodermal tissue development.

The production of recombinant EDA involves cloning the EDA gene into expression systems (e.g., mammalian cells or bacteria) to ensure proper protein folding and post-translational modifications, which are critical for receptor binding and biological activity. Advances in protein engineering have improved stability and bioavailability, enabling preclinical and clinical studies. For instance, intra-amniotic injections of recombinant EDA have shown promise in restoring sweat gland function in XLHED-affected animal models and human trials.

Beyond therapeutic applications, EDA recombinant protein is utilized in research to study ectodermal development, signaling mechanisms, and tissue regeneration. Its role in regulating epithelial-mesenchymal interactions also makes it relevant for regenerative medicine and bioengineering. Overall, EDA recombinant protein represents a bridge between molecular biology and clinical innovation, offering hope for genetic disorders and insights into developmental biology.